Research Project
7135419
[unreadable] DESCRIPTION (provided by applicant): The detection and enumeration of circulating tumor cells (CTC) has the potential to become a very powerful tool in cancer diagnosis and treatment. However, current technologies for CTC detection are not yet established in routine clinical practice. 1 primary reason is that CTCs present in body fluids at extremely low concentrations of 1 in 1 million or more normal hetergeneous cells. Existing technologies lack the sensitivity and specificity required for reliable and reproducible detection of these rare CTCs. Another reason is that current technology does not distinguish well the "live" from "dead" or "dying" CTCs. The overall goal of this research proposal is to develop an assay technology named QMAGEX for Quantitative Multiplex Analysis of Gene Expression in Single Cells in Suspension and to utilize the technology for sensitive detection, accurate enumeration, and functional analysis of CTCs in body fluids. The long-term goal of this effort is to leverage this assay technology to develop a suite of high value cancer diagnostic products. These products would satisfy many significant unmet needs in cancer diagnosis, especially in the areas of early detection, therapy guidance, and recurrence monitoring. The research effort described in this Phase I SBIR application represents the first, "proof-of-concept" step towards the long-term goal. Well characterized breast and prostate cancer cell lines will be used as a model system and detection and enumeration of CTC at a clinically useful concentration (1 CTC in every 10,000 normal white blood cells) will be demonstrated. If successful, Phase II effort will be aimed at developing high information content QMAGEX assay for detection of CTC at a concentration below 1 in 1 to 10 million normal white blood cells. The assay will be tested in real clinical blood or bone marrow samples and their clinical utility evaluated. Commercial diagnostic products focusing on specific cancers and specific diagnostic applications will be developed in Phase III. [unreadable] [unreadable] [unreadable]
